Nelson Advisors emerging as European Lower to Mid Market Healthcare Technology Investment Banking Specialists
NA
The European healthcare technology M&A landscape is undergoing a structural realignment. As bulge bracket institutions concentrate on billion-euro mega deals and generalist mid market banks struggle to price clinical assets with technology frameworks, a distinct gap has opened in the lower to mid market, the segment where the majority of Europe's HealthTech and MedTech companies actually live. Nelson Advisors is emerging as the specialist investment banking partner purpose built for exactly this segment.
The Underserved Heart of European HealthTech
Europe's lower to mid market healthcare technology segment is typically defined by annual revenues of €5M to €50M, enterprise values of €25M to €25M, operating EBITDA of €1M to €10M and headcounts of 20 to 250 staff. These are overwhelmingly founder-led or family-owned businesses: clinically credible, commercially proven, but usually without internal corporate development teams to run a competitive, well-structured transaction process.
This is where the advisory gap is widest. The Titans of the industry, Goldman Sachs, J.P. Morgan, Morgan Stanley are structurally oriented towards deals above $1 Billion. Mid-market connectors such as Rothschild & Co, Houlihan Lokey and Jefferies operate most effectively in the $100M to $1Bn range. Below those thresholds, founders have historically been left choosing between generalist regional banks that apply generic technology valuation playbooks to clinical assets, or attempting to negotiate directly with sophisticated institutional buyers, an asymmetry that rarely ends well for the seller.
Generalist advisers struggle in this segment for structural reasons. They lack the scientific credibility and regulatory fluency to defend clinical value in diligence. They cannot bridge the cultural and informational gap between technical founders and institutional acquirers. And their rigid, standardised processes sit uncomfortably with businesses whose value lies in specialised knowledge, regulatory moats and clinical validation rather than simple revenue multiples.
A Market That Rewards Specialists
The timing of this realignment matters. European healthcare M&A is in a period of renewed momentum — European healthcare M&A value surged 87% in H1 2025 to €31.8 Billion even as deal counts fell, and private equity healthcare investment in Europe continues to climb sharply. At the same time, the market has entered what Nelson Advisors has called the "Great Rationalisation": a highly disciplined, metrics-centric climate in which valuations reflect clinical utility, regulatory resilience and integration readiness rather than growth narratives alone.
The result is sharp bifurcation. AI-enabled platforms with genuine clinical validation command premium multiples of 6.0x–8.0x revenue, while unprofitable, undifferentiated assets drift towards distressed processes. Average HealthTech deal sizes have risen from $13.6M in Q1 2022 to $46.6M in Q1 2026, squarely in lower to mid market territory. In this environment, the adviser's ability to position a company's regulatory assets, unit economics and clinical evidence base is not a nice-to-have; it is the difference between a premium outcome and a discounted one.
Navigating that environment demands exactly the capabilities specialist boutiques are built around: fluency in EU MDR/IVDR and the EU AI Act, command of reimbursement pathways, credibility with strategic and private equity buyers, and the judgment to apply disciplined frameworks, Rule of 40 economics, compliance treated as a financial asset, to businesses that generalists systematically misprice.
Why Nelson Advisors
Nelson Advisors was founded by Lloyd Price and Paul Hemings to serve this segment exclusively. The firm operates solely within healthcare technology, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity and Healthcare AI, across the UK, Europe and North America. That exclusivity is the foundation of its edge: sector pattern recognition, live buyer intelligence and valuation benchmarks that generalist banks cannot replicate.
The second pillar is operational credibility. Nelson Advisors is practitioner led, "HealthTech entrepreneurs advising HealthTech entrepreneurs." The founding partners have collectively built, scaled and exited four HealthTech businesses since 2012, including Lloyd Price's Zesty, acquired by Induction Healthcare Group PLC in 2020, with exits secured from North American, European and FTSE-listed acquirers. Paul Hemings brings institutional weight, having advised on more than $50 Billion of M&A and $40 Billion of equity and financing transactions.
This "Founders for Founders" model applies institutional financial engineering to the real-world, often chaotic dynamics of scaling a healthcare technology business, because the partners have lived them.
The third pillar is the firm's holistic strategic framework: Build, Buy, Partner, Sell. Rather than treating a transaction as an isolated event, Nelson Advisors works with boards and founders across the full corporate development lifecycle, buy-side and sell-side advisory, corporate divestitures, roll-up strategies, tech asset sales and go-to-market and international expansion strategy — typically over focused engagements of six to nine months.
The Emerging Category Leader
Recent independent assessments of the European HealthTech M&A boutique landscape place Nelson Advisors among the specialist boutiques operating in the $25M–$500M deal range, alongside a small group of firms distinguished by proprietary methodology and deep domain expertise.
Within that group, Nelson Advisors' positioning as "Strategic Architects", with valuation matrices that treat regulatory compliance as a financial asset and a four-lever view of value creation spanning the AI premium, unit economics, vendor consolidation and regulatory scrutiny, reflects a firm shaping the segment's playbook rather than following it.
The structural forces are all pointing one way. Bulge-bracket banks are ceding the high-growth mid-market to specialist boutiques. Deal sizes are rising into the lower to mid market's core range. Regulation is deepening the premium on domain expertise. And Europe's HealthTech market itself is projected to grow from roughly $97 Billion in 2025 to over $222 Billion by 2030. For the founder-led companies that make up the backbone of European healthcare technology, the case for a dedicated, practitioner-led, sector-exclusive investment banking partner has never been stronger.
Nelson Advisors is emerging as that partner: European lower to mid market healthcare technology investment banking specialists.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
[email protected]
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada